Where there is inflammation,treatment may reduce disability progression

Abstract

Get full access to this article

View all access options for this article.

References

Edan

. Where there is inflammation, treatment may reduce disability progression – No. Mult Scler 2018; 24: 1810–1812.

Kalincik

. Where there is inflammation, treatment may reduce disability progression – Yes. Mult Scler; 24: 1808–1810.

Kappos

Bar-Or

Cree

BAC

et al . Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet 2018; 391: 1263–1273.

Montalban

Hauser

Kappos

et al . Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376: 209–220.

Lizak

Lugaresi

Alroughani

et al . Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. J Neurol Neurosurg Psychiatry 2017; 88: 196–203.

Magliozzi

Howell

Reeves

et al . A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68: 477–493.

Serafini

Rosicarelli

Magliozzi

et al . Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164–174.

Lucchinetti

Popescu

Bunyan

et al . Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365: 2188–2197.

Howell

Reeves

Nicholas

et al . Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011; 134: 2755–2771.

10.

Magliozzi

Howell

Vora

et al . Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130: 1089–1104.

11.

Kutzelnigg

Lucchinetti

Stadelmann

et al . Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705–2712.

12.

Confavreux

Vukusic

Moreau

et al . Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430–1438.

13.

Martino

Adorini

Rieckmann

et al . Inflammation in multiple sclerosis: The good, the bad, and the complex. Lancet Neurol 2002; 1: 499–509.

14.

Kappos

Moeri

Radue

et al . Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999; 353: 964–969.

15.

Zhang

Tremlett

Zhu

et al . Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology 2018; 90: e419–e427.

Where there is inflammation,treatment may reduce disability progression – Commentary

Abstract

Get full access to this article

References